Related Experiment Video
Updated: Mar 24, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects,
Robert H Shoemaker1, Chen S Suen1, Cathy A Holmes2
1Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program whose primary goal is to bring new cancer preventive interventions (small molecules and vaccines) and biomarkers through preclinical development towards clinical trials by creating partnerships between the public sector (eg, academia, industry) and DCP. PREVENT has a formalized structure for moving interventions forward in the prevention pipeline using a stage-gate process with go/no go decision points along the critical path for development. This review describes the structure of the program, its focus areas, and provides examples of projects currently in the pipeline.
Insights
The PREVENT program accelerates cancer prevention interventions from lab to clinical trials. It uses a structured stage-gate process and public-private partnerships to advance novel small molecules, vaccines, and biomarkers.
Area of Science:
- Oncology
- Translational Science
- Drug Development
Background:
- The National Cancer Institute's Division of Cancer Prevention (NCI, DCP) supports the PREVENT Cancer Preclinical Drug Development Program (PREVENT).
- PREVENT aims to advance cancer preventive interventions and biomarkers through preclinical development.
- A key objective is to foster collaborations between public sector entities (academia, industry) and the NCI, DCP.
Purpose of the Study:
- To describe the structure and focus areas of the PREVENT program.
- To provide examples of projects currently undergoing preclinical development within the PREVENT pipeline.
- To highlight the stage-gate process used for moving interventions forward.
Main Methods:
- The PREVENT program utilizes a formalized stage-gate process.
- Decision points (go/no go) are integrated into the critical path for development.
- Partnerships between academia, industry, and the NCI, DCP are central to the program's operation.
Main Results:
- The review outlines the operational framework of the PREVENT program.
- Specific focus areas for cancer prevention interventions are detailed.
- Illustrative examples of ongoing projects are presented, showcasing the program's progress.
Conclusions:
- The PREVENT program provides a structured pathway for advancing cancer prevention candidates.
- Its collaborative model facilitates the transition of promising interventions towards clinical application.
- The program's stage-gate process ensures rigorous evaluation and progression of drug development projects.
